HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.61825-94-3
|
| Oxaliplatin Basic information |
| Treatment of colorectal cancer Adverse reactions and side effects Chemical Properties Application production method |
| Product Name: | Oxaliplatin |
| Synonyms: | [SP-4-2-(1R-TRANS)]-(1,2-CYCLOHEXANEDIAMINE-N,N')[ETHANEDIOATA(2-)-O,O']PLATINUM;OXALIPLATIN;trans-l-diaminocyclohexane oxalatoplatinum;(1,2-cyclohexanediamine-n,n’)(ethanedioato(2-)-o,o’)-platinu(sp-4-2-(1r-tr;1-ohp;oxalato(1r,2r-cyclohexanediammine)platinum(ii);oxalatoplatin;oxalatoplatinum |
| CAS: | 61825-94-3 |
| MF: | C8H14N2O4Pt |
| MW: | 397.29 |
| EINECS: | 274-613-9 |
| Product Categories: | Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;APIs;Amines;Heterocycles;chemical reaction,pharm,electronic,materials;PRAXILENE;Inhibitors |
| Mol File: | 61825-94-3.mol |
|
|
|
| Oxaliplatin Chemical Properties |
| storage temp. | Store at +4°C |
| form | solid |
| Stability: | Stable. Store cool. Incompatible with oxidizing agents. |
| Safety Information |
| Hazard Codes | Xn,Xi |
| Risk Statements | 36/37/38-40-42/43 |
| Safety Statements | 26-36 |
| RIDADR | 2811 |
| WGK Germany | 3 |
| RTECS | TP2275850 |
| HazardClass | 6.1(a) |
| PackingGroup | II |
| Oxaliplatin Usage And Synthesis |
| Treatment of colorectal cancer |
Oxaliplatin belongs to platinum derivatives for the treatment of patients with colorectal cancer metastasis after the failure of the clinical treatment through fluorouracil , it can be used alone or in combination with the use of fluorouracil, it is the third generation of new class of anti-tumor platinum compounds for colorectal cancer after cisplatin and carboplatin , and so far it has been the only envelope platinum drug which has a significant activity. The Principle is by producing alkylation conjugate to act on DNA, to form crosslinks within the chain and between the chain which inhibit DNA synthesis and replication.at the same time, it can inhibit the hyperplasia of ovarian cancer and melanoma cell lines. August 2002, the US Food and Drug Administration (FDA) approved the Sanofi Saint raborg company's anticancer drug oxaliplatin (, Eloxatin) for the second-line treatment of metastatic colon cancer. January 2004, the US Food and Drug Administration (FDA) formally approved the injection of oxaliplatin (Eloxatin) and 5-fluorouracil (5FU) and leucovorin (LV) Joint (FOLFOX program) for the first-line treatment of advanced colorectal cancer. The domestic market is currently dominated by Sanofi - Aventis (Eloxatin); Jiangsu Hengrui Medicine Co., Ltd. (Oxaliplatin); Jiangsu Nanjing Pharmaceutical (Austrian platinum) three manufacturers monopoly, which occupy more than 85% of the domestic market share . |
| Adverse reactions and side effects |
1, the hematopoietic system: oxaliplatin has some hematologic toxicity. When administered alone,it can cause the following adverse reactions: anemia, leukopenia, neutropenia, thrombocytopenia, sometimes up to grade 3 or 4. When in combination with 5-fluorouracil , neutropenia and thrombocytopenia diseases’ hematological toxicity increases . 2, the digestive system:When administered alone, it can cause nausea, vomiting, diarrhea. These symptoms sometimes are very serious. When in combination with 5-fluorouracil, these side effects are increased significantly. It is Recommended to give preventive and / or therapeutic anti-emetic medication . 3,the nervous system: peripheral neuritis, characterized by peripheral sensory neuropathy. Sometimes there are accompanied around the mouth, upper respiratory tract and upper digestive tract spasms and sensory disorders. The above information is edited by the Chemicalbook of Tian Ye. |
| Chemical Properties | Triangular flaky colorless crystals. The water solubility is 7.9mg / ml. |
| Application | For the treatment of colorectal cancer. |
| production method | 5g of trans-cyclohexanediamine and 18g K2 (PtCl4) aqueous solution react at room temperature for 12h, to give 12g intermediate product (I). 6: 8g of silver nitrate is added to 3g Compound (I) aqueous solution , the mixture is stirred for 2 ~ 3h under the dark, then add 4.8g oxalic acid dipotassium salt, react for 8h at room temperature , oxaliplatin is obtained . |
| Chemical Properties | White Crystalline Solid |
| Usage | Third generation platinum complex. An antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA. Antineoplastic. |
| Usage | vasodilator |
| Usage | A antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA |
| Biological Activity | Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (cis-Diaminodichloroplatinum ) and shows antitumor activity in cell lines with acquired cisplatin resistance. |